Literature DB >> 7529108

Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1.

L J Murphy1, R Corder, A I Mallet, A J Turner.   

Abstract

1. Phosphoramidon, a potent inhibitor of endopeptidase-24.11 (E-24.11) and thermolysin, has been shown to reduce the hypertensive effect of exogenous big endothelin-1 (big ET-1) in rats. To examine whether E-24.11 or thermolysin convert big ET-1 to endothelin-1 (ET-1) and C-terminal fragment (CTF), the effects on porcine and human big ET-1 of each of the purified enzymes were compared in vitro. 2. For E-24.11, the relative rates of hydrolysis were ET-1 > CTF >> big ET-1. The relative half-lives for hydrolysis of 3 nmol of each peptide by 200 ng enzyme were: big ET-1 > 24 h; ET-1, 37 min; CTF, 57 min. For comparison, the half-life for hydrolysis of substance P under similar conditions was 2.1 min. 3. For thermolysin the relative rates of hydrolysis were found to be big ET-1 > CTF > ET-1. The relative half-lives for hydrolysis of 3 nmol peptide by 50 ng enzyme were: big ET-1, 25 min; ET-1, 56 min; CTF, 47 min. 4. Because the low rate of conversion of big ET-1 to ET-1 by E-24.11 did not yield sufficient ET-1 for h.p.l.c. quantification a RIA specific for ET-1(16-21) was used to study further the hydrolysis of big ET-1 by E-24.11. Incubation of big ET-1 (0.2-2 nmol) with E-24.11 (4-400 ng) generated ET-1 levels of between 1.7 and 33 pmol measured by RIA. Incubation of big ET-1 (2 nmol) with E-24.11 (40 ng) for 8 h showed that steady state levels of ET-1 were achieved after 4 h indicating that the rate of ET-1 degradation was then equal to the formation of new ET-1. Characterization of the immunoreactivity by h.p.l.c. and RIA confirmed that authentic ET-1 had been produced, but the yield was insufficient for verification by mass spectrometry.5. Both ET-l-like and CTF-like peaks were detected at 214 nm when the products of big ET-1 hydrolysis by thermolysin were resolved by h.p.l.c. RIA and mass spectrometry confirmed the production of ET-1 with amounts in the range 120-160 pmol.6. The hydrolysis profile of ET-1 by E-24.11 and thermolysin shows that both enzymes have some common cleavage sites consistent with their similar specificities hydrolysing on the amino side of a hydrophobic residue.7. Thermolysin, for which 3D structural information is available, may represent a better model for endothelin converting enzyme (ECE) action than E-24.11 and could be useful for the design of ECE inhibitors. Since E-24.11 can both synthesize and hydrolyse ET-1, the presence of E-24.11 in membrane fractions or in partially purified ECE preparations may produce misleading estimates of ECE activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529108      PMCID: PMC1510048          DOI: 10.1111/j.1476-5381.1994.tb16185.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Letter: A thermolysin inhibitor produced by Actinomycetes: phospholamidon.

Authors:  H Suda; T Aoyagi; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1973-10       Impact factor: 2.649

2.  Reaction of neutral endopeptidase 24.11 (enkephalinase) with arginine reagents.

Authors:  D G Jackson; L B Hersh
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

3.  A monoclonal antibody to kidney endopeptidase-24.11. Its application in immunoadsorbent purification of the enzyme and immunofluorescent microscopy of kidney and intestine.

Authors:  N S Gee; R Matsas; A J Kenny
Journal:  Biochem J       Date:  1983-08-15       Impact factor: 3.857

4.  Presence of a histidine at the active site of the neutral endopeptidase-24.11.

Authors:  A Beaumont; B P Roques
Journal:  Biochem Biophys Res Commun       Date:  1986-09-14       Impact factor: 3.575

5.  Structure of a mercaptan-thermolysin complex illustrates mode of inhibition of zinc proteases by substrate-analogue mercaptans.

Authors:  A F Monzingo; B W Matthews
Journal:  Biochemistry       Date:  1982-07-06       Impact factor: 3.162

6.  Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors.

Authors:  I S Fulcher; R Matsas; A J Turner; A J Kenny
Journal:  Biochem J       Date:  1982-05-01       Impact factor: 3.857

7.  Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin.

Authors:  M Pozsgay; C Michaud; M Liebman; M Orlowski
Journal:  Biochemistry       Date:  1986-03-25       Impact factor: 3.162

8.  Comparison of the subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin.

Authors:  L B Hersh; K Morihara
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

9.  Processing and metabolism of endothelin peptides by porcine lung membranes.

Authors:  L J Murphy; K J Greenhough; A J Turner
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

10.  Binding of N-carboxymethyl dipeptide inhibitors to thermolysin determined by X-ray crystallography: a novel class of transition-state analogues for zinc peptidases.

Authors:  A F Monzingo; B W Matthews
Journal:  Biochemistry       Date:  1984-11-20       Impact factor: 3.162

View more
  7 in total

Review 1.  Vasopeptidase inhibition: effective blood pressure control for vascular protection.

Authors:  Thomas Quaschning; Frank Ruschitzka; Thomas F Lüscher
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

Review 2.  Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.

Authors:  Sanjaya Kuruppu; Niwanthi W Rajapakse; A Ian Smith
Journal:  Pflugers Arch       Date:  2013-01-18       Impact factor: 3.657

Review 3.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

4.  Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

Authors:  C Plumpton; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

5.  Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats.

Authors:  K S Park; Y Li; Y Zhang; A L Gerbes; H Liu; M G Swain; S S Lee
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells.

Authors:  J C Yu; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

7.  Cyclic expression of endothelin-converting enzyme-1 mediates the functional regulation of seminiferous tubule contraction.

Authors:  A Tripiciano; C Peluso; A R Morena; F Palombi; M Stefanini; E Ziparo; M Yanagisawa; A Filippini
Journal:  J Cell Biol       Date:  1999-05-31       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.